Join our mailing list.
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
This study is currently recruiting participants.
The purpose of this trial is to assess the efficacy and safety of E7777 (improved purity ONTAK) in patients with persistent and recurrent cutaneous T-cell lymphoma. A lead-in dose-finding part will be used to determine the dose of E7777 that should be used to test efficacy and safety.
Study Type: Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Conditions: Persistent or Recurrent Cutaneous T-Cell Lymphoma
Intervention: Drug: E7777
Phase: Phase 3
External Link: https://clinicaltrials.gov/ct2/show/NCT01871727
NCT01796002
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma
View Clinical Trial InformationNCT01352520
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
View Clinical Trial InformationNCT01777152
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
View Clinical Trial InformationNCT01738594
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
View Clinical Trial InformationNCT01728805
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
View Clinical Trial InformationNCT01626664
KW-0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
View Clinical Trial InformationNCT01660451
Open-label, Uncontrolled Phase II Trial of Intravenous P13K Inhibitor BAY80-6946 in Patients with Relapsed, Indolent or Aggressive Non-Hodgkin’s Lymphomas
View Clinical Trial InformationNCT01431209
Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
View Clinical Trial InformationNCT01678443
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoid Malignancies
View Clinical Trial InformationNCT01261247
Panobinostat in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
View Clinical Trial InformationNCT01703949
Brentuximab Vedotin in Treating Patients with Relapsed or Refractory CD30+ Lymphoma
View Clinical Trial InformationNCT02535247
This is a multicenter, single-arm, open label 2-stage phase 2 study exploring monotherapy with the PD-1 antibody pembrolizumab in patients with PTCL.
View Clinical Trial InformationNCT02168140
This trial studies the side effects and best dose of CPI-613 when given together with bendamustine hydrochloride in different conditions.
View Clinical Trial InformationNCT01947140
This is a study to test how safe the combination of romidepsin and pralatrexate are in patients with lymphoid malignancies and determine dosage.
View Clinical Trial InformationNCT01998035
This is a dose escalation study with an initial phase 1 followed by a disease focused phase 2. Its primary objective is to determine MTD and DLT.
View Clinical Trial InformationNCT02520791
This phase 1 trial studies the side effects and best dose of ICOS monoclonal antibody MEDI-570 in treating patients with PTCL follicular variant.
View Clinical Trial InformationNCT01431209
This phase 2 trial studies how well giving ruxolitinib phosphate works in treating patients with peripheral T-cell non-hodgkin lymphoma.
View Clinical Trial InformationNCT02232516
The purpose of this study is to evaluate how safe and effective the combination of romidepsin and lenalidomide is for treating patients with PTCL.
View Clinical Trial InformationNCT02341014
This is an open label phase 1b/2a study of patients with relapsed/refractory B- and T-cell lymphomas who are treated in a 3+3 design.
View Clinical Trial InformationNCT02561273
This phase 1/2 trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy in patients with NHL.
View Clinical Trial InformationNCT02576496
This study is to evaluate the efficacy, safety and pharmacokinetics of EDO-S101 in patients with relapsed or refractory hematologic malignancies.
View Clinical Trial InformationNCT02783625
The purpose of this study is to test the safety of a study drug called duvelisib.
View Clinical Trial InformationNCT02495415
To address the hypothesis that intermittent treatment with fenretinide intravenous emulsion will induce objective responses in patients with PTCL.
View Clinical Trial InformationNCT02448381
To evaluate the use of SGX301 to treat patients with patch/plaque phase cutaneous T-cell lymphoma.
View Clinical Trial InformationNCT02580552
This is a two-part study to evaluate the safety of MRG-106 in patients with CTCL, mycosis fungoides subtype.
View Clinical Trial InformationNCT02464228
This study is designed to investigate the antitumor activity of tipifarnib in subjects with advanced PTCL.
View Clinical Trial InformationNCT02309580
This is a Phase 1 clinical trial to find out whether ibrutinib is safe in patients with relapsed and refractory T-Cell non-Hodgkin lymphoma.
View Clinical Trial InformationNCT02588651
This study will include patients with MTCL that has been treated with at least one type of chemotherapy, but is not responding.
View Clinical Trial InformationNCT02192021
This study is to test if MNA-directed chemo-immunotherapy using doxorubicin will kill tumor cells locally to induce durable systemic immnunity.
View Clinical Trial InformationNCT01902225
This is a Phase 1 efficacy study of the combination of romidepsin in combination with Doxil for adult patients with relapsed or refractory CTCL.
View Clinical Trial InformationNCT01738594
This randomized phase 1 trial studies the side effects and best dose of carfilzomib when given with or without romidepsin in treating CTCL.
View Clinical Trial InformationNCT01871727
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
View Clinical Trial InformationNCT02106650
This study is to evaluate the effect of leucovorin in preventing or reducing Folotyn-related Grade 3 or higher oral mucositis.
View Clinical Trial InformationNCT03542266
This is a phase II, multi-center study to determine the efficacy and safety of first-line CC-486 plus CHOP in patients with PTCL who have received no prior systemic therapy.
View Clinical Trial InformationNCT02341209
This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.
View Clinical Trial InformationNCT03927105
A multicenter trial evaluating the combination of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
View Clinical Trial InformationNCT03586999
Patients in this study will receive nivolumab in combination with the standard of care dose-adjusted EPOCH (etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide) for six 21 day cycles.
View Clinical Trial InformationNCT03075553
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment.
View Clinical Trial InformationNCT03278782
This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that does not respond to treatment.
View Clinical Trial InformationNCT03598998
This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment.
View Clinical Trial Information
Patient Support
Specialists